NEW YORK (GenomeWeb) – Bruker announced last week that it has acquired PCR technology assets with which it plans to build syndromic infectious disease diagnostics.

The assets include a laboratory in Glasgow, UK and intellectual property related to PCR. The company has also hired research and business staff to support the development, validation, and commercialization of the syndromic microbiology panels, Wolfgang Pusch, executive vice president for clinical MALDI solutions at Bruker, told GenomeWeb.